{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:12:52Z","timestamp":1790853172990,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.pcad.2020.09.006","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T13:26:16Z","timestamp":1601299576000},"page":"649-655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Diagnostic and prognostic considerations for use of natriuretic peptides in obese patients with heart failure"],"prefix":"10.1016","volume":"63","author":[{"given":"Shruti","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian J.","family":"Neeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pcad.2020.09.006_bb0005","doi-asserted-by":"crossref","first-page":"H17","DOI":"10.1152\/ajpheart.00684.2005","article-title":"Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications","volume":"290","author":"Clerico","year":"2006","journal-title":"American Journal of Physiology-Heart and Circulatory Physiology"},{"issue":"9380","key":"10.1016\/j.pcad.2020.09.006_bb0010","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0140-6736(03)13976-1","article-title":"B-type natriuretic peptide in cardiovascular disease","volume":"362","author":"de Lemos","year":"2003","journal-title":"Lancet (London, England)"},{"issue":"9061","key":"10.1016\/j.pcad.2020.09.006_bb0015","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0140-6736(96)07424-7","article-title":"The natriuretic-peptide family","volume":"349","author":"Wilkins","year":"1997","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.pcad.2020.09.006_bb0020","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.3390\/ijms20081820","article-title":"BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine","volume":"20","author":"Cao","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.pcad.2020.09.006_bb0025","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.amjcard.2004.12.032","article-title":"The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study","volume":"95","author":"Januzzi","year":"2005","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2020.09.006_bb0030","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMoa020233","article-title":"Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure","volume":"347","author":"Maisel","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1016\/j.pcad.2020.09.006_bb0035","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1161\/CIRCULATIONAHA.105.555573","article-title":"Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas heart study","volume":"112","author":"Das","year":"2005","journal-title":"Circulation."},{"issue":"5","key":"10.1016\/j.pcad.2020.09.006_bb0040","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.0000112582.16683.EA","article-title":"Impact of obesity on plasma natriuretic peptide levels","volume":"109","author":"Wang","year":"2004","journal-title":"Circulation."},{"issue":"9","key":"10.1016\/j.pcad.2020.09.006_bb0045","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jacc.2003.10.066","article-title":"Obesity and suppressed B-type natriuretic peptide levels in heart failure","volume":"43","author":"Mehra","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.pcad.2020.09.006_bb0050","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1742-4658.2011.08082.x","article-title":"Natriuretic peptide metabolism, clearance and degradation","volume":"278","author":"Potter","year":"2011","journal-title":"FEBS J"},{"issue":"1 Suppl","key":"10.1016\/j.pcad.2020.09.006_bb0055","article-title":"Salt-regulating hormones in young normotensive obese subjects. . Effects of saline load","volume":"23","author":"Licata","year":"1994","journal-title":"Hypertension (Dallas, Tex\u202f: 1979)"},{"issue":"12","key":"10.1016\/j.pcad.2020.09.006_bb0060","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.2337\/db09-0393","article-title":"Natriuretic peptides\/cGMP\/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity","volume":"58","author":"Miyashita","year":"2009","journal-title":"Diabetes."},{"issue":"3","key":"10.1016\/j.pcad.2020.09.006_bb0065","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1172\/JCI59701","article-title":"Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes","volume":"122","author":"Bordicchia","year":"2012","journal-title":"J Clin Invest"},{"issue":"22","key":"10.1016\/j.pcad.2020.09.006_bb0070","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.jacc.2009.02.038","article-title":"Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure","volume":"53","author":"Tsukamoto","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.pcad.2020.09.006_bb0075","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jacc.2013.03.038","article-title":"Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile","volume":"62","author":"Neeland","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.pcad.2020.09.006_bb0080","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/BF03349021","article-title":"Expression of natriuretic peptide receptors in human adipose and other tissues","volume":"19","author":"Sarzani","year":"1996","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"10.1016\/j.pcad.2020.09.006_bb0085","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1096\/fasebj.14.10.1345","article-title":"Natriuretic peptides: a new lipolytic pathway in human adipocytes","volume":"14","author":"Sengen\u00e8s","year":"2000","journal-title":"Faseb J"},{"issue":"13","key":"10.1016\/j.pcad.2020.09.006_bb0090","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1161\/CIRCULATIONAHA.117.029617","article-title":"Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management","volume":"137","author":"Neeland","year":"2018","journal-title":"Circulation."},{"issue":"11","key":"10.1016\/j.pcad.2020.09.006_bb0095","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.jacc.2018.01.021","article-title":"N-terminal pro-B-type natriuretic peptide in the emergency department: the ICON-RELOADED study","volume":"71","author":"Januzzi","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2020.09.006_bb0100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jacc.2005.08.050","article-title":"B-type natriuretic peptide levels in obese patients with advanced heart failure","volume":"47","author":"Horwich","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2020.09.006_bb0105","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijcard.2016.04.111","article-title":"Potent influence of obesity on suppression of plasma B-type natriuretic peptide levels in patients with acute heart failure: an approach using covariance structure analysis","volume":"215","author":"Kinoshita","year":"2016","journal-title":"Int J Cardiol"},{"issue":"20","key":"10.1016\/j.pcad.2020.09.006_bb0110","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1001\/archinte.164.20.2247","article-title":"Relationship between obesity and B-type natriuretic peptide levels","volume":"164","author":"McCord","year":"2004","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.pcad.2020.09.006_bb0115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.14740\/cr898","article-title":"Importance of basal metabolic index in the diagnosis of heart failure with B-type natriuretic peptide","volume":"10","author":"Ullah","year":"2019","journal-title":"Cardiology research"},{"issue":"5","key":"10.1016\/j.pcad.2020.09.006_bb0120","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ahj.2005.10.011","article-title":"How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the breathing not properly multinational study","volume":"151","author":"Daniels","year":"2006","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.pcad.2020.09.006_bb0125","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1373\/clinchem.2009.129742","article-title":"Impact of increased body mass index on accuracy of B-type natriuretic peptide (BNP) and N-terminal proBNP for diagnosis of decompensated heart failure and prediction of all-cause mortality","volume":"56","author":"Christenson","year":"2010","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.pcad.2020.09.006_bb0130","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/archinte.167.4.400","article-title":"Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea","volume":"167","author":"Bayes-Genis","year":"2007","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.pcad.2020.09.006_bb0135","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ehf2.12235","article-title":"Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction","volume":"5","author":"Buckley","year":"2018","journal-title":"ESC heart failure"},{"issue":"6","key":"10.1016\/j.pcad.2020.09.006_bb0140","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.ahj.2006.07.010","article-title":"B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures","volume":"152","author":"Taylor","year":"2006","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.pcad.2020.09.006_bb0145","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1527-5299.2006.04900.x","article-title":"Obese patients have lower B-type and atrial natriuretic peptide levels compared with nonobese","volume":"12","author":"Khush","year":"2006","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.pcad.2020.09.006_bb0150","first-page":"61","article-title":"BNP and obesity in acute decompensated heart failure with preserved vs reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study International","volume":"233","author":"Khalid","year":"2017","journal-title":"Journal of Cardiology"},{"key":"10.1016\/j.pcad.2020.09.006_bb0155","article-title":"Body composition, natriuretic peptides, and adverse outcomes in heart failure with preserved and reduced ejection fraction","author":"Selvaraj","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.pcad.2020.09.006_bb0160","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.hrtlng.2017.01.005","article-title":"Relationship among body mass index, NT-proBNP, and mortality in decompensated chronic heart failure","volume":"46","author":"Scrutinio","year":"2017","journal-title":"Heart & lung\u202f: the journal of critical care"},{"issue":"3","key":"10.1016\/j.pcad.2020.09.006_bb0165","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006740","volume":"7","author":"Bhatt","year":"2018","journal-title":"Journal of the American Heart Association"},{"issue":"22","key":"10.1016\/j.pcad.2020.09.006_bb0170","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1161\/CIRCULATIONAHA.116.024976","volume":"134","author":"Nadruz","year":"2016","journal-title":"Circulation."},{"issue":"21","key":"10.1016\/j.pcad.2020.09.006_bb0175","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009664","article-title":"Body mass index, natriuretic peptides, and risk of adverse outcomes in patients with heart failure and preserved ejection fraction: analysis from the TOPCAT trial","volume":"7","author":"Pandey","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.pcad.2020.09.006_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214363","article-title":"Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction - a report from FAR NHL prospective registry","volume":"14","author":"Spinar","year":"2019","journal-title":"PloS one"},{"issue":"23","key":"10.1016\/j.pcad.2020.09.006_bb0185","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/eurheartj\/ehu090","article-title":"Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis","volume":"35","author":"Troughton","year":"2014","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.pcad.2020.09.006_bb0190","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.2017.10565","article-title":"Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"318","author":"Felker","year":"2017","journal-title":"JAMA."},{"issue":"8","key":"10.1016\/j.pcad.2020.09.006_bb0195","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","volume":"23","author":"Yancy","year":"2017","journal-title":"J Card Fail"},{"issue":"6","key":"10.1016\/j.pcad.2020.09.006_bb0200","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"Heart failure Association of the European Society of cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.pcad.2020.09.006_bb0205","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa020245","article-title":"Obesity and the risk of heart failure","volume":"347","author":"Kenchaiah","year":"2002","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.pcad.2020.09.006_bb0210","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000490","article-title":"Role of biomarkers for the prevention, assessment, and Management of Heart Failure: a scientific statement from the American Heart Association","volume":"135","author":"Chow","year":"2017","journal-title":"Circulation."}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062020301626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062020301626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:19:01Z","timestamp":1758500341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062020301626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0033062020301626"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2020.09.006","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic and prognostic considerations for use of natriuretic peptides in obese patients with heart failure","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2020.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}